Merck & Co and Bayer agree their own asset-swapping megadeal
This article was originally published in Scrip
Executive Summary
Bayer has won the auction for Merck & Co's consumer care business with a cash offer of $14.2bn. The companies also plan to collaborate in the field of sGC (soluble guanylate cyclase) modulators, for which Merck will make an upfront payment to Bayer of $1bn.
You may also be interested in...
Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
Up Front Or Back End? Considering The Best Structure For Milestone Fees
PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.